Under the terms of the agreement, KineMed will apply its proprietary technologies to find alternative applications for discontinued compounds formerly in Organon’s clinical-stage pipeline.
Once therapeutic utility is established for a selected drug candidate, KineMed and Organon will jointly determine a development and commercialization path, including a potential joint development and commercialization program.
“We at Organon are dedicated to maximize the potential of R&D compounds. KineMed’s ability to measure the outputs of complex pathways in in vivo studies may lead to the discovery of new indications and as such holds great promise,” said David Nicholson, executive vice president of global R&D at Organon.